---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-001631"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:42:54.270226+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mirum Q3 revenue $47.7M, LIVMARLI sales up 106%; CHENODAL/CHOLBAM acquisition completed

## Summary
- Q3 2023 total revenue $47.7M (up 154% YoY); LIVMARLI global net sales $38.7M, +106% vs Q3 2022.
- Acquisition of CHENODAL and CHOLBAM closed Aug 31; contributed $9M in Q3 sales.
- Positive Phase 3 RESTORE for CHENODAL in CTX; NDA filing expected H1 2024; sNDA for LIVMARLI in PFIC PDUFA March 13, 2024.
- Cash and investments $306M; convertible debt $316.3M; pipeline catalysts: EMBARK data by year-end, volixibat data H1 2024.

## SEC filing metadata
- accession: 0001157523-23-001631
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000115752323001631/0001157523-23-001631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000115752323001631/a53739737.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-001631
- JSON: https://secwatch.observer/filing/0001157523-23-001631.json
- Plain text: https://secwatch.observer/filing/0001157523-23-001631.txt

## Key facts
- Earnings Releases
  Mirum Pharmaceuticals, Inc. reported third quarter 2023 results: revenue $47.7 million.
  - Period: third quarter 2023
  - Revenue: $47.7 million
  - Result: reported results
  source text: EXHIBIT 99.1 Exhibit 99.1 Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update - Third quarter 2023 total revenue of $47.7 million - Completed acquisition of CHENODAL® and CHOLBAM® - Announced positive Phase 3 RESTORE study results evaluating CHENODAL (chenodiol) in patients with CTX; NDA filing expected in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000115752323001631/0001157523-23-001631-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.